CommercialCoverageMedium impact
Intravenous Iron Replacement Therapy
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology, Nephrology +4 more·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 20, 2026
Summary
Blue Cross & Blue Shield of Mississippi has implemented a new policy designating four specific intravenous iron replacement medications (Feraheme brand, Ferrlecit brand, Injectafer, and Monoferric) as not medically necessary due to available formulary alternatives. Both the medications and their administration services will not be covered.
Action Required
Before January 1, 2025: Billing team must update systems to flag HCPCS codes J1437 (ferric derisomaltose) and J1439 (ferric carboxymaltose) as non-covered for BCBS Mississippi plans. Providers should be notified to use formulary-approved IV iron alternatives instead. Claims for these medications and their administration will be denied.